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Abstract
The synthesis and characterization of di-n-butyltin and dimethyltin salicyloxamate, respectively compounds 1
and 2, are reported. Compound 1 is more active than cisplatin, 5-fluorouracil and etoposide against seven
tumoural cell lines of human origin, but less active than methotrexate and doxorubucin.
Diorganotin derivatives of salicylic acid and its substituted analogs exhibit antitumour activities in vitro
against human tumoural cell lines 1,2. The phenolic hydroxy group of salicylic acid is not involved in its
reaction with diorganotin oxides3,4. In fact, salicylic acid behaves in this respect as benzoic acid, giving rise to
diorganotin disalicylates with free hydroxy groups.
This report presents the synthesis and characterization of di-n-butyltin and dimethyltin salicyloxamate,
respectively compounds 1 and 2, in order to find out whether the phenolic hydroxy group of salicyloxamic
acid is involved when reacting with diorganotin oxides. The antitumour activity of compound 1 was
determined for comparison with that of the corresponding di-n-butyltin salicylate5.
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Compound 1, a viscous oil, and compound 2, a solid (m.p. 195-197) were synthesized with 94% and 85%
yield, respectively, by condensing the appropriate diorganotin oxide with salicyloxamic acid in a
toluene/ethanol 4/1 mixture3,6,7. They were purified by chromatography on Sephadex LH-20 with
chloroform/ethanol 99/1 as eluent (compound 1) or crystallization from dichloromethane/hexane 50/50
(compound 2). IH and 13C NMR data (CDC13) are given in Table 1. The ll7Sn NMR chemical shifts of
compounds 1 and 2 are respectively -140.0 and -100.2 ppm. The cationic mode electrospray mass spectra of
compounds 1 and 2 exhibit the fragment corresponding to (M + H+) (100%) at resp. m/z 386
(CIsHz4NO3Sn) and 302 (C9HzNO3Sn) with the expected isotopic distribution.
Compound 1 was tested in vitro against seven tumoural cell lines of human origin: MCF-7 et EVSA-T, two
mammary turnouts, WiDr, a colon carcinoma, IGROV, an ovarian cancer, M 19 MEL, a melanoma, A498, a
renal cancer, and H226, a non-small cell lung cancer, as water/ethanol 99/1 solutions.
The results of the antitumoural tests are summarized in Table 2 and compared with the inhibition doses IDs0
found against MCF-7 and WiDr for di-n-butyltin disalicylate and bis(acetylsalicylate), as well as those
obtained for some clinically used reference compounds8,9, cis-platin, 5-fluorouracil, etoposide, methotrexate
and doxorubicin. Compound 1 has, especially against WiDr, a markedly higher in vitro activity than di-n-
butyltin disalicylate and bis(acetylsalicylate) as well as cisplatin, 5-fluorouracil and etoposide. Its activity is
lower than that of methotrexate and doxorubicin, except for H-226 against which compound 1 exhibits a very
low inhibition dose as compared to all other compounds.
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IH 13C
1 2 1 2
H2 d: 6.54 [8] d: 6.55 [8]
H3 dd: 6.79 [8,8] dd: 6.80 [8,8]
H4 dd: 7.28 [8,8] dd: 7.30 [8,8]
H5 d: 7.88 [8] d: 7.90 [8]
CI 162.7 162.1
C2 119.5 119.6
C3 116.8 116.2
C4 133.0 133.1
C5 129.6 129.6
C6 116.3 116.2
C7 163.3 163.4
H8 s: 13.62 (55) s: 13.60 (55)
Ha s: 0.84 (76/73) Ca 22.7 (590/564)
Ha_l m: 1.75-1.52 C[ 26.8 (31)
H, tq: 1.37 [7,7] C, 26.6 (88)
H5 t: 0.87 [7] C5 13.6
2.1 (639/611)
Table 1: 1H and 13C NMR data of compounds 1 and 2 (CDCI3). Chemical shifts in ppm vs. TMS; nj(1H,1H) (between
brackets), nj(1H,ll9/ll7Sn)and nj(13C,119/ll7Sn) (bold in parentheses) coupling constants in Hz. d: doublet; t:
triplet; tq: triplet of quartets; s: singlet; m: complex pattern.
MCF-7 EVSA-T WiDr IGROV M19 MEL A498 H226
1 67 59 316 103 90 140 109
Di-n-butyltin disalicylate 540 2974
Di-n-butyltin bis(acetylsalicylate) 283 2495
Cisplatin 699 422 967 169 558 2253 3269
5-Fluorouracil 750 475 225 297 442 143 340
Etoposide 2594 317 150 580 505 1314 3934
Methotrexate 18 5 <3 7 23 37 2287
Doxorubicin 10 8 11 60 16 90 199
Table 2. Inhibition doses ID50 of compound 1 as compared to di-n-butyltin disalicylate and bis(acetylsalicylate)5
and of some reference compounds8,9 against tumoural cell lines of human origin.
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